NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
April 19, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
March 22, 2024 17:04 ET
|
NurExone Biologic Inc
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
March 15, 2024 16:05 ET
|
NurExone Biologic Inc
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
March 08, 2024 16:05 ET
|
NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
March 01, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
NurExone’s Intellectual Property Portfolio Expands
February 20, 2024 16:05 ET
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Launches Licensing Efforts for ExoTherapy Platform
February 14, 2024 16:20 ET
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
February 02, 2024 16:05 ET
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
January 17, 2024 08:34 ET
|
NurExone Biologic Inc
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
January 05, 2024 08:30 ET
|
NurExone Biologic Inc
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million